Pharynx neoplasm

Summary

Pharynx neoplasm (MONDO:0021246) is a cancer (an umbrella term covering 7 Mondo subtypes) and 3 clinical trials. Top therapeutic interventions include cetuximab. A subtype of digestive system neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 7 Mondo subtypes
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pharynx neoplasm
Mondo ID	MONDO:0021246
ICD-10-CM	C00-C14
NCIT	C3325
UMLS	C0031347
MedGen	45844
Anatomy (UBERON)	UBERON:0006562
Is cancer (heuristic)	yes

Also known as: neoplasm of pharynx · neoplasm of the pharynx · pharyngeal neoplasms · pharyngeal tumor · pharyngeal tumour · pharynx neoplasm (disease) · pharynx tumor · pharynx tumour · tumor of pharynx · tumor of the pharynx · tumour of pharynx · tumour of the pharynx

Disease family

This is a subtype of digestive system neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › digestive system neoplasm › pharynx neoplasm

Related subtypes (22): benign digestive system neoplasm, hepatobiliary neoplasm, digestive system cancer, digestive system adenoma, gastrointestinal hamartoma, malignant epithelial tumor of salivary glands, benign epithelial tumor of salivary glands, pancreatic neoplasm, gastric neoplasm, gingival neoplasm, intestinal neoplasm, odontogenic neoplasm, tongue neoplasm, buccal mucosa neoplasm, oral cavity neoplasm, lip neoplasm, neoplasm of esophagus, tumor of salivary gland, neoplasm of floor of mouth, neoplasm of jaw, digestive system neuroendocrine neoplasm, odontoma

Subtypes (7): nasopharyngeal neoplasm, pharynx cancer, tonsil neoplasm, carcinoma of pharynx, neoplasm of hypopharynx, neoplasm of oropharynx, benign neoplasm of pharynx

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01216020	PHASE2	TERMINATED	Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer
NCT00396617	PHASE1	UNKNOWN	Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy
NCT01171235	Not specified	UNKNOWN	Study of Biomarker From Blood and Tissue of Head and Neck Carcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CETUXIMAB	4	1